Chugai Seiyaku Kabushiki Kaisha

Nagoya University

Kyowa Hakko Kirin Co., Limited

Fujifilm Corporation

The University of Tokyo

Kyowa Hakko Kogyo Co., Ltd.

National Hospital Organization

Aichi Prefecture

Tomoki Naoe

Hitoshi Kiyoi

Yukimasa Shiotsu

Toshio Kitamura

Masayuki Towatari

Hiroshi Umehara

Yutaka Kanda

Fumihiko Kanai

Shinji Nara

Yoshihisa Ohta

Keiko Kawashima

Hiromi Ando

Motoki Miyama

Yoshinori Yamashita

Masaru Takasaki

Hitoshi Arai

Hiroyuki Mano

Tsutomu Matsumura

Shinji Hagiwara

Hiroshi Ishida

Koji Hagihara

Akihiro Tomita

Junji Hiraga

Masahito Kawazu

Fumihiko Hayakawa

Syoichi Isami

Toshihide Ueno

Daisuke Hirano

Toshiyuki Nakatani

Nana Oiwa

Takeshi Yamaura

Takahiko Yasuda

Shinobu Tsuzuki

Shinji c/o Drug Discovery Research Laboratories Kyowa Hakko Kirin Co Ltd Nara

Fumihiko c/o Head Office Kyowa Hakko Kirin Co Ltd Kanai

Yoshihisa c/o Head Office Kyowa Hakko Kirin Co Ltd Ohta

Yukimasa c/o Biologics Research Laboratories Kyowa Hakko Kirin Co Ltd Shiotsu

Hiroshi c/o Drug Discovery Research Laboratories Kyowa Hakko Kirin Co Ltd Umehara

Motoki c/o Head Office Kyowa Hakko Kirin Co Ltd Miyama

Hiromi c/o Head Office Kyowa Hakko Kirin Co Ltd Ando

Yutaka c/o Medical Chemistry Research Laboratories Kyowa Hakko Kirin Co Ltd Kanda

An object of the present invention is to provide a method for determining whether a subject suffers from malignant lymphoma or leukemia and an agent for treating and/or preventing the disease. The present invention relates to a method for assisting in determining whether a subject suffers from, or is likely to suffer from malignant lymphoma or leukemia, comprising: a detection step of detecting at least one of a fusion mutation of a DUX4 gene, an overexpression of a DUX4 gene, and a fusion mutation of an MEF2D gene; and a determination step of determining that the subject suffers from or is likely to suffer from the disease when at least one of the fusion mutations or the overexpression is detected. Moreover, the present invention relates to a pharmaceutical composition comprising a DUX4 inhibitor as an active ingredient, for treating and/or preventing malignant lymphoma or leukemia in a subject having a fusion mutation of a DUX4 gene and an IGH or IGL gene and/or overexpression of a DUX4 gene.

Method for determining presence or absence of suffering from malignant lymphoma or leukemia, and agent for treatment and/or prevention of leukemia

Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation. 

Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof

It is intended to provide a tool, a procedure and so on which are useful in developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug. Thus, a CD20-negatively converted B-cell malignant lymphocyte cell line is provided. Also, a model animal indicating the pathological conditions of CD20-negatively converted B-cell malignant lymphocyte is provided. Further, a method of screening a substance, which is efficacious against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, is provided. Furthermore, a drug against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B-cell malignant lymphocyte, which is characterized by being used together with a CD20-directed molecular-targeted drug, is provided. In one embodiment, a DNA methylase inhibitor or a histone deacetylase inhibitor is employed as the active ingredient.

CD20 negatively converted B-cell malignant lymphoma cell line and utilization thereof

Investigation on the frequency of FLT3/ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3/ITD in the blood cell lines revealed that the tyrosine residues in FLT3/ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3/ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3/ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3/ITD functions as an index.

Method for screening candidate compounds for antitumor drug

The present invention provides an antitumor agent and the like, which comprises as an active ingredient, a pyrimidine derivative represented by Formula (I): [wherein &#x2014;X&#x2014;Y&#x2014;Z&#x2014; represents &#x2014;O&#x2014;CR&#x2550;N&#x2014; (wherein Rrepresents a hydrogen atom, a substituted or unsubstituted aromatic heterocyclic group and the like) and the like, Rrepresents &#x2014;NRR(wherein Rand Rmay be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like) and the like, Rrepresents &#x2014;NRR(wherein Rand Rmay be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like)] or a pharmaceutically acceptable salt thereof.

Pyrimidine derivative compound

The present invention provides a compound represented by Formula (I): [wherein Rrepresents CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like,Rrepresents a hydrogen atom, CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].

Indazole derivatives

The present invention provides a compound represented by Formula (I): [wherein Rrepresents CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like,

Method and screening candidate compounds for drug against tumor

Growing community of inventors

Aichi, Japan

Tomoki Naoe